coagulation factor xiii a-subunit (recombinant) (Tretten) Report issue

Biologics Recombinant protein Orphan Drug FDA Approved FDA
AACT ChEMBL DrugBank Drug Central KEGG PubChem repoDB

Active Ingredient History

NOW
  • Now
Catridecacog, sold under the brand name Tretten in the US and NovoThirteen in the EU) is a class of recombinant factor XIII A-subunit based biopharmaceutical medicine, indicated in patients with a rare clotting disorder, congenital factor XIII A-subunit deficiency, which is a kind of Factor XIII deficiency. The medication prevents bleeding in patients with this condition, and has been approved by the U.S. Food and Drug Administration (FDA) for this use in the US in 2014. It was brought to market by Novo Nordisk.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

blood coagulation factor xiii (synthetic human a-chain precursor) | catridecacog | catridecacog (genetical recombination) | coagulation factor xiii | coagulation factor xiii a subunit (recombinant) | coagulation factor xiii a-subunit (recombinant) | factor xiii | factor xiii a-subunit (recombinant) | human factor xiii (a2) homodimer (allele f13a*1b), recombinant dna origin | novothirteen | recombinant coagulation factor xiii | tretten

Organizations (1)

Research & Development (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (4)

Approved Indications (1)


 

Hemophilia B (approved 2013)

Experimental Indications - Clinical Trial Phases 1-4 (3)


 

Deficiency Diseases (Phase 1)

Healthy Volunteers (Phase 1)

Hemophilia A (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial Organizations: 1

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue